CN111886008B - 用于抗mers-冠状病毒治疗的组合物和方法 - Google Patents

用于抗mers-冠状病毒治疗的组合物和方法 Download PDF

Info

Publication number
CN111886008B
CN111886008B CN201880080271.9A CN201880080271A CN111886008B CN 111886008 B CN111886008 B CN 111886008B CN 201880080271 A CN201880080271 A CN 201880080271A CN 111886008 B CN111886008 B CN 111886008B
Authority
CN
China
Prior art keywords
mers
cov
cells
viral
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880080271.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN111886008A (zh
Inventor
袁硕峰
陈福和
朱轩
刘耀南
袁国勇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Versitech Ltd
Original Assignee
Avalon Yellow Virus Treatment Hong Kong Ltd
Versitech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avalon Yellow Virus Treatment Hong Kong Ltd, Versitech Ltd filed Critical Avalon Yellow Virus Treatment Hong Kong Ltd
Publication of CN111886008A publication Critical patent/CN111886008A/zh
Application granted granted Critical
Publication of CN111886008B publication Critical patent/CN111886008B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201880080271.9A 2017-10-18 2018-10-16 用于抗mers-冠状病毒治疗的组合物和方法 Active CN111886008B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762573933P 2017-10-18 2017-10-18
US62/573,933 2017-10-18
PCT/US2018/056138 WO2019079339A1 (en) 2017-10-18 2018-10-16 COMPOSITIONS AND METHODS FOR BROAD SPECTRUM ANTIVIRAL THERAPY

Publications (2)

Publication Number Publication Date
CN111886008A CN111886008A (zh) 2020-11-03
CN111886008B true CN111886008B (zh) 2024-05-31

Family

ID=66173467

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880080271.9A Active CN111886008B (zh) 2017-10-18 2018-10-16 用于抗mers-冠状病毒治疗的组合物和方法

Country Status (6)

Country Link
US (1) US12213955B2 (https=)
EP (1) EP3697404B1 (https=)
JP (1) JP7466907B2 (https=)
CN (1) CN111886008B (https=)
TW (1) TWI860281B (https=)
WO (1) WO2019079339A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018089306A1 (en) 2016-11-10 2018-05-17 Oyagen, Inc. Methods of treating and inhibiting ebola virus infection
CN112789925B (zh) * 2019-06-27 2023-06-02 Oppo广东移动通信有限公司 用于指示空间关系信息的方法和设备
US11738025B2 (en) 2020-02-04 2023-08-29 Oyagen, Inc. Method for treating coronavirus infections
AU2021235899A1 (en) * 2020-03-08 2022-10-13 Humanigen, Inc. Methods for treating coronavirus infection and resulting inflammation-induced lung injury
US11628165B1 (en) * 2020-03-25 2023-04-18 Helen Feng Method of boosting immune system against viral infection
ES2862462B2 (es) * 2020-04-06 2023-04-27 Servicio Andaluz De Salud Compuestos para la profilaxis y/o el tratamiento del sindrome de dificultad respiratoria aguda
WO2021211738A1 (en) * 2020-04-15 2021-10-21 Sanford Burnham Prebys Medical Discovery Institute Methods and compositions for antiviral treatment
WO2021226479A1 (en) * 2020-05-07 2021-11-11 The Regents Of The University Of California Inhaled statins for treatment of viral respiratory diseases
BR112022023746A2 (pt) * 2020-05-22 2023-02-07 Alberto Riveros Carlos Sistema, método e uso de um determinado medicamento para reduzir a replicação viral na mucosa das vias aéreas
WO2021249240A1 (zh) * 2020-06-11 2021-12-16 养生堂有限公司 Palovarotene在抗hbv病毒治疗中的用途
US20240131036A1 (en) * 2020-07-02 2024-04-25 The Uab Research Foundation Compositions and methods of treating conditions
CN112390731B (zh) * 2020-11-16 2022-11-25 成都大学 一种具有多靶点的维甲酸类衍生物及其制备方法与应用
US11998562B2 (en) 2021-01-25 2024-06-04 University Of South Florida Ophthalmological formulations for the prevention of a coronavirus infection
CN117062611A (zh) 2021-01-26 2023-11-14 惠和生物技术(上海)有限公司 嵌合抗原受体（car）构建体和表达car构建体的nk细胞
US20220378727A1 (en) * 2021-05-14 2022-12-01 The University Of Hong Kong Dry powder formulations of tamibarotene for pulmonary and intranasal delivery
CN116891497B (zh) * 2022-04-02 2025-12-16 上海旭成医药科技有限公司 视黄酸受体激动剂、其制备方法、中间体、药物组合物和应用
WO2023210634A1 (ja) * 2022-04-28 2023-11-02 国立大学法人東海国立大学機構 拡張障害を伴う心不全の治療用医薬組成物
CN119454680B (zh) * 2024-12-06 2025-06-17 华南农业大学 贝沙罗汀在制备抗prrsv或治疗猪蓝耳病的药物中的应用
CN121177272A (zh) * 2025-11-10 2025-12-23 北京市农林科学院 化合物am580在预防或治疗塞内卡病毒病中的用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005120479A1 (en) * 2004-06-09 2005-12-22 Gpc Biotech Ag Use of selenium or a selenium salt and a retinoid acid or a retinoid in the treatment of viral hepatitis c
WO2014079709A1 (en) * 2012-11-23 2014-05-30 Ab Science Use of small molecule inhibitors/activators in combination with (deoxy)nucleoside or (deoxy)nucleotide analogs for treatment of cancer and hematological malignancies or viral infections

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7341717B2 (en) 2001-04-13 2008-03-11 Gpc Biotech Ag Therapeutic targets for treatment of HCV infections, methods of treating HCV infections and compounds useful therefor
US20060151574A1 (en) * 2002-11-29 2006-07-13 Gpc Biotech Ag Formulations useful against hepatitis C virus infections
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
ES2609825T3 (es) * 2007-01-18 2017-04-24 Evolva Sa 1,3-Dioxanos sustituidos útiles como moduladores de PPAR
CN104662036B (zh) * 2012-04-25 2018-11-09 华辉安健（北京）生物科技有限公司 乙肝肝炎病毒功能性受体的组成以及相关应用
KR20160113302A (ko) 2014-02-18 2016-09-28 칠드런＇스 하스피틀 로스 앤젤레스 호중구감소증을 치료하기 위한 조성물 및 방법
CA2942469C (en) * 2014-03-10 2024-06-11 Cornell University Combination therapy for head and neck cancer
WO2018054891A1 (en) 2016-09-20 2018-03-29 Ruprecht-Karls-Universität Compounds and combinations thereof for preventing and/or treating hbv and/or hdv infections

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005120479A1 (en) * 2004-06-09 2005-12-22 Gpc Biotech Ag Use of selenium or a selenium salt and a retinoid acid or a retinoid in the treatment of viral hepatitis c
WO2014079709A1 (en) * 2012-11-23 2014-05-30 Ab Science Use of small molecule inhibitors/activators in combination with (deoxy)nucleoside or (deoxy)nucleotide analogs for treatment of cancer and hematological malignancies or viral infections

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Harry D Dawson et.al..The Retinoic Acid Receptor-α mediates human T-cell activation and Th2 cytokine and chemokine production.《BMC Immunology》.2008,第9卷(第16期),1-14. *
Retinoid derivative Tp80 exhibits anti-hepatitis C virus activity through restoration of GI-GPx expression;Bao Ngoc Nguyen等;《Journal of Medical Virology》;20170328;第89卷(第7期);第1-29页 *

Also Published As

Publication number Publication date
TWI860281B (zh) 2024-11-01
US20200338032A1 (en) 2020-10-29
EP3697404B1 (en) 2025-03-26
JP7466907B2 (ja) 2024-04-15
CN111886008A (zh) 2020-11-03
EP3697404A1 (en) 2020-08-26
JP2021500400A (ja) 2021-01-07
TW201927293A (zh) 2019-07-16
WO2019079339A1 (en) 2019-04-25
US12213955B2 (en) 2025-02-04
EP3697404A4 (en) 2021-07-21

Similar Documents

Publication Publication Date Title
CN111886008B (zh) 用于抗mers-冠状病毒治疗的组合物和方法
Yuan et al. SREBP-dependent lipidomic reprogramming as a broad-spectrum antiviral target
Yi et al. Natural triterpenoids from licorice potently inhibit SARS-CoV-2 infection
Xu et al. Broad spectrum antiviral agent niclosamide and its therapeutic potential
Prajapat et al. Drug targets for corona virus: A systematic review
Boriskin et al. Arbidol: a broad-spectrum antiviral compound that blocks viral fusion
Yuan et al. Targeting papain-like protease for broad-spectrum coronavirus inhibition
Wang et al. Triggering unfolded protein response by 2-Deoxy-D-glucose inhibits porcine epidemic diarrhea virus propagation
Laure et al. Antiviral efficacy against influenza virus and pharmacokinetic analysis of a novel MEK-inhibitor, ATR-002, in cell culture and in the mouse model
Ke et al. Porcine reproductive and respiratory syndrome virus nsp4 positively regulates cellular cholesterol to inhibit type I interferon production
US20140121237A1 (en) Methods for Inhibiting Virus Replication
Li et al. Cholesterol 25-hydroxylase inhibits encephalomyocarditis virus replication through enzyme activity-dependent and independent mechanisms
Kathiravan et al. An overview of spike surface glycoprotein in severe acute respiratory syndrome–coronavirus
Ma-Lauer et al. Oxysterole-binding protein targeted by SARS-CoV-2 viral proteins regulates coronavirus replication
Tang et al. A selective SARS-CoV-2 host-directed antiviral targeting stress response to reactive oxygen species
EP3773550A1 (en) Soce facilitators for use in treating or preventing viral infections
Tang et al. Peptide-based inhibitors hold great promise as the broad-spectrum agents against coronavirus
Raj et al. Current understanding on molecular drug targets and emerging treatment strategy for novel coronavirus-19
Li et al. SIRT5-mediated desuccinylation of the porcine deltacoronavirus M protein drives pexophagy to enhance viral proliferation
Liu et al. Coronaviral nsp6 hijacks ERAD machinery to facilitate lipolysis and supply membrane components for DMV growth
Li et al. Differential Bioactivation Profiles of Different GS-441524 Prodrugs in Cell and Mouse Models: ProTide Prodrugs with High Cell Permeability and Susceptibility to Cathepsin A Are More Efficient in Delivering Antiviral Active Metabolites to the Lung
Luo et al. Diacylglycerol O-acyltransferase 2, a novel target of flavivirus NS2B3 protease, promotes Zika virus replication by regulating lipid droplet formation
HK40038027A (en) Compositions and methods for anti-mers-coronavirus therapy
HK40038027B (zh) 用於抗mers-冠状病毒治疗的组合物和方法
EP4532511A1 (en) Novel main protease inhibitors, and compositions and methods thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20210406

Address after: Room 405a, Cyberport phase 4, 100 Cyberport Road, Hong Kong, China

Applicant after: VERSITECH Ltd.

Address before: 10 / F, Fung house, 19-20 Connaught Road, central, Hong Kong, China

Applicant before: Avalon yellow virus treatment (Hong Kong) Ltd.

Applicant before: VERSITECH Ltd.

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40038027

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant